Stuttgart
17.09.26 | 17:17
21,680 Euro
0,00 % 0,000
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 21,320 | 22,120 | 17:33 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20.08. | XVIVO erhält CE-Zertifikate für bahnbrechende Technologie zur Herzkonservierung | 9.325 | news aktuell | Göteborg/Berlin (ots) - - Die CE-Zertifizierungen ermöglichen den breiteren Einsatz der innovativen XVIVO-Technologie und verbessert den Zugang zu Herztransplantationen in Europa. XVIVO gibt die CE-Zertifizierungen... ► Artikel lesen | |
| XVIVO PERFUSION Aktie jetzt für 0€ handeln | |||||
| 11.08. | Xvivo Perfusion AB: XVIVO receives CE certificates for its groundbreaking heart preservation technology, transforming access to life-saving transplants across Europe | 354 | GlobeNewswire (Europe) | CAUTION-Investigational device in the US. Limited by Federal (United States) law to investigational use. The safety and effectiveness of this device have not been established. The XVIVO heart technology... ► Artikel lesen | |
| 03.08. | XVIVO Perfusion AB: XVIVO Granted Additional Patient Enrollment in the US PRESERVE CAP Study for XVIVO Heart Assist Transport | 406 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / August 3, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - XVIVO announces that the US Food and Drug Administration (FDA) has granted the company approval... ► Artikel lesen | |
| 14.07. | Xvivo Perfusion AB (publ) reports Q2 results | 3 | Seeking Alpha | ||
| 14.07. | Xvivo Perfusion AB Q2 Profit Rises | 3 | RTTNews | ||
| 14.07. | XVIVO übertrifft im Q2 die Umsatzerwartungen dank starkem Thorax-Geschäft | 1 | Investing.com Deutsch | ||
| 14.07. | XVIVO Perfusion AB: Interim Report January - June 2026 | 521 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / July 14, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)Second quarter 2026 (Apr-Jun)Net sales amounted to SEK 239.0 million (178.3), corresponding to a growth... ► Artikel lesen | |
| 09.07. | OneLegacy Partners with XVIVO and Perfusion Solution to Launch the First Ex Vivo Lung Perfusion (EVLP) Center in the Western U.S. | 384 | Business Wire | OneLegacy, the nonprofit organ procurement organization serving Southern California, announced the launch of the first in-house Ex Vivo Lung Perfusion (EVLP) program at an organ procurement organization... ► Artikel lesen | |
| 26.06. | XVIVO Perfusion AB: Conference call on Interim Report April-June 2026 | 480 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / June 26, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Invitation to attend XVIVO's conference call regarding the interim report April-June 2026. The... ► Artikel lesen | |
| 18.05. | XVIVO Perfusion AB: Regulatory Derogation and Reimbursement in France Enable Life-Saving Use of XVIVO's Heart Technology | 411 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / May 18, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Hôpital La Pitié-Salpêtrière (Sorbonne University) in Paris, France, has, since the approval of... ► Artikel lesen | |
| 27.04. | Bulletin from Annual General Meeting in XVIVO Perfusion AB | 333 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 27, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV):The following resolutions were passed at the Annual General Meeting (the "AGM") of XVIVO Perfusion... ► Artikel lesen | |
| 24.04. | Xvivo Perfusion AB (publ) GAAP EPS of SEK1.15, revenue of SEK241M | 1 | Seeking Alpha | ||
| 24.04. | XVIVO Perfusion AB: Interim Report January - March 2026 | 228 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 24, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)First quarter 2026 (Jan-Mar)Net sales amounted to SEK 241.0 million (218.6), corresponding to growth... ► Artikel lesen | |
| 24.04. | Xvivo Perfusion AB: Interim Report January - March 2026 | 255 | GlobeNewswire (Europe) | First quarter 2026 (Jan-Mar)• Net sales amounted to SEK 241.0 million (218.6), corresponding to growth of 10 percent in SEK.• Organic growth was 23 percent in local currencies. Excluding revenue from... ► Artikel lesen | |
| 22.04. | XVIVO Perfusion AB: XVIVO Presents Encouraging Results From First Clinical Trial Using Hypothermic Oxygenated Perfusion In Direct Procurement DCD Heart Transplantation | 532 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 22, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Today, the results from the HOPE-at-Heart clinical trial (NCT06485596) were presented at the ISHLT... ► Artikel lesen | |
| 22.04. | XVIVO Perfusion AB: Preliminary One-Year Follow-up Data From the US Preserve Trial for XVIVO's Heart Technology Presented at ISHLT in Toronto | 467 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 22, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Today, preliminary one-year follow-up data from the US PRESERVE trial of XVIVO's investigational... ► Artikel lesen | |
| 22.04. | Late-Breaking Data from PRESERVE Trial Evaluates XVIVO's HOPE Preservation Approach in Heart Transplantation | 488 | Business Wire | Preliminary results suggest potential to support extended preservation time and donor heart utilization XVIVO, a global medtech company in the organ transplant industry, today announced late-breaking... ► Artikel lesen | |
| 17.04. | XVIVO Perfusion AB: Conference Call on Interim Report January-March 2026 | 394 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 17, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Invitation to attend XVIVO's conference call regarding the interim report January-March 2026.... ► Artikel lesen | |
| 16.04. | XVIVO Perfusion AB: The 12-Month Follow-up Results from XVIVO's European Multicenter Heart Trial is Now Published in the European Heart Journal | 376 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 16, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - At last year's ISHLT congress, in April 2025, the one-year results from the European multicenter... ► Artikel lesen | |
| 02.04. | Xvivo Perfusion AB (publ) GAAP EPS of SEK 0.80, revenue of SEK 812.2M | 4 | Seeking Alpha |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CARL ZEISS MEDITEC | 29,300 | -3,30 % | EQS-DD: Carl Zeiss Meditec AG: Andreas Pecher, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
10.09.2026 / 15:20... ► Artikel lesen | |
| ECKERT & ZIEGLER | 12,260 | +1,91 % | Eckert&Ziegler-Aktie im Check am 17.09. (08:16 Uhr): Meine aktuelle Lageeinschätzung | ||
| INTUITIVE SURGICAL | 330,65 | -0,77 % | Can AI Keep ISRG Ahead of Rising Robotic Surgery Competition? | ||
| RHOEN-KLINIKUM | 14,300 | 0,00 % | 13. September ist Welt-Sepsis-Tag / Alle sechs Minuten stirbt in Deutschland ein Mensch an Sepsis - RHÖN-KLINIKUM Campus Bad Neustadt setzt auf Früherkennung | Bad Neustadt a.d. Saale (ots) - Mit 85.000 Todesfällen pro Jahr ist Sepsis die dritthäufigste Todesursache. Verbindliches Schulungsprogramm für alle medizinischen Mitarbeitenden - Früherkennung und... ► Artikel lesen | |
| BICO GROUP | 2,010 | +6,35 % | BICO Group AB: Publication of BICO Group AB: Interim Report Q2 2026 | Improved profitability and AI advancements
"In the quarter we had a continued solid momentum with growth in our bench top instruments and consumables businesses, while still experiencing challenges... ► Artikel lesen | |
| M1 KLINIKEN | 20,700 | -2,82 % | M1 Kliniken steigert Beauty-Gewinn deutlich | M1 Kliniken hat im Kerngeschäft Beauty im ersten Halbjahr 2026 den Umsatz um 11 Prozent von 51,2 Millionen auf 56,9 Millionen Euro gesteigert. Das Segment-EBIT wuchs deutlich stärker um 23,8 Prozent... ► Artikel lesen | |
| BAXTER | 20,500 | -0,05 % | Dividendenbekanntmachungen (28.08.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) 361 DEGREES INTERNATIONAL LTD KYG884931042 0,222 HKD 0,0243 EUR ABC-MART INC JP3152740001 40 JPY 0,2152 EUR ADMIE IPTO HOLDING... ► Artikel lesen | |
| ASENSUS SURGICAL | - | - | Karl Storz to fully integrate Asensus, discontinue Senhance, Luna robots | ||
| JD HEALTH INTERNATIONAL | 3,751 | -2,00 % | JD HEALTH (06618): 2026 INTERIM REPORT | ||
| COOPER COMPANIES | 47,000 | -1,27 % | Aktien New York: Verluste - Fed rückt wegen Ölpreis und EZB in den Fokus | NEW YORK (dpa-AFX) - Nach den Verlusten im bisherigen Wochenverlauf bleiben die US-Börsen auch am Donnerstag unter Druck. Weiterhin wird die Stimmung von den Entwicklungen im Nahost-Konflikt und den... ► Artikel lesen | |
| LIFEWARD | 6,910 | 0,00 % | Lifeward legt Termin für jährliche und außerordentliche Hauptversammlung 2026 fest | ||
| BONESUPPORT | 19,770 | +2,17 % | Bonesupport Holding AB: BONESUPPORT HOLDING AB (publ) - publishes Q2 2026 interim report | BONESUPPORT HOLDING AB (publ), a leading company in orthobiologics for the management of bone injuries, today publishes the interim report for the second quarter 2026.
"Strong growth and improved operating... ► Artikel lesen | |
| NANO-X IMAGING | 0,764 | +1,42 % | Nano-X Imaging Ltd: Nanox Expands Latin American Presence with Nanox.ARC Distribution Agreement in Costa Rica | Agreement with SOLME RC, SA Marks the third Latin American market this year PETACH TIKVA, Israel, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Nanox Imaging Ltd. (NASDAQ: NNOX) ("Nanox"), a leader in innovative... ► Artikel lesen | |
| IMPLANTICA | 5,360 | +0,56 % | Implantica's Capital Markets Day webcast available on demand | VADUZ, Liechtenstein, Sept. 11, 2026 /PRNewswire/ -- Implantica AG (publ.) would like to thank all who attended its Capital Markets Day in Stockholm on September 9, 2026.
A recording of the... ► Artikel lesen | |
| SURGICAL SCIENCE SWEDEN | 4,264 | -4,86 % | Surgical Science Sweden AB: Interim report January-June 2026: Strong license revenue and improved profitability | Second quarter 2026 (April-June)Net sales amounted to SEK 254.5 (209.2) million, an increase of 22 percent compared with the corresponding period in the preceding year. Calculated in local currencies... ► Artikel lesen |
Das Unternehmen XVIVO PERFUSION AB kann der Branche Gesundheitswesen zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 21,680 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu XVIVO PERFUSION AB finden Sie auf Wallstreet Online.